Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
Status:
Terminated
Trial end date:
2021-06-28
Target enrollment:
Participant gender:
Summary
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered
SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or
metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.